Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L. Hijazi Z, et al. Among authors: reilly pa. Am Heart J. 2017 Aug;190:94-103. doi: 10.1016/j.ahj.2017.06.001. Epub 2017 Jun 6. Am Heart J. 2017. PMID: 28760218 Clinical Trial.
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Eikelboom JW, et al. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16. Circulation. 2011. PMID: 21576658 Clinical Trial.
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Healey JS, et al. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Circulation. 2012. PMID: 22700854 Clinical Trial.
Dabigatran etexilate and reduction in serum apolipoprotein B.
Joseph P, Pare G, Wallentin L, Connolly S, Yusuf S, Wang J, Ezekowitz M, Eikelboom J, Siegbahn A, Reilly P, Themeles E, Oldgren J; RE-LY Investigators. Joseph P, et al. Heart. 2016 Jan;102(1):57-62. doi: 10.1136/heartjnl-2015-307586. Epub 2015 Nov 9. Heart. 2016. PMID: 26552755 Clinical Trial.
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
Flack KF, Desai J, Kolb JM, Chatterjee P, Wallentin LC, Ezekowitz M, Yusuf S, Connolly S, Reilly P, Brueckmann M, Ilgenfritz J, Aisenberg J. Flack KF, et al. Clin Gastroenterol Hepatol. 2017 May;15(5):682-690. doi: 10.1016/j.cgh.2016.10.011. Epub 2016 Oct 17. Clin Gastroenterol Hepatol. 2017. PMID: 27765728 Clinical Trial.
182 results